These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35140513)

  • 1. Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry.
    Ueberall MA; Essner U; Vila Silván C; Mueller-Schwefe GHH
    J Pain Res; 2022; 15():267-286. PubMed ID: 35140513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry.
    Ueberall MA; Vila Silván C; Essner U; Mueller-Schwefe GHH
    Pain Med; 2022 Apr; 23(4):745-760. PubMed ID: 34480564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry.
    Ueberall MA; Essner U; Mueller-Schwefe GH
    J Pain Res; 2019; 12():1577-1604. PubMed ID: 31190969
    [No Abstract]   [Full Text] [Related]  

  • 4. COMET - effectiveness and tolerability of methocarbamol versus oral opioid-analgesics as add-on measure in patients with non-specific low back pain refractory to recommended 1st line treatments. A retrospective analysis of depersonalized propensity score matched open-label real-world 4-week data from the German Pain e-Registry.
    Ueberall MA; Mueller-Schwefe G
    Curr Med Res Opin; 2022 Feb; 38(2):237-253. PubMed ID: 34767467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain.
    Überall MA
    J Pain Res; 2020; 13():399-410. PubMed ID: 32104061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [No Abstract]   [Full Text] [Related]  

  • 9. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry.
    Ueberall MA; Horlemann J; Schuermann N; Kalaba M; Ware MA
    Pain Med; 2022 Aug; 23(8):1409-1422. PubMed ID: 35104881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
    Hoggart B; Ratcliffe S; Ehler E; Simpson KH; Hovorka J; Lejčko J; Taylor L; Lauder H; Serpell M
    J Neurol; 2015 Jan; 262(1):27-40. PubMed ID: 25270679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
    Serpell M; Ratcliffe S; Hovorka J; Schofield M; Taylor L; Lauder H; Ehler E
    Eur J Pain; 2014 Aug; 18(7):999-1012. PubMed ID: 24420962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J; Feneberg W; Meier M; Pöllmann W
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
    Patti F
    Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
    J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.